Hosted on MSN20h
MAIA’s lung cancer therapy 99% more likely to improve OS over chemo alone
A treatment for patients living with advanced non-small cell lung cancer (NSCLC) who failed two or more standard-of-care (SOC ...
MAIA Biotechnology Announces Positive Efficacy Updates for Phase 2 THIO-101 Trial in Advanced Non-Small Cell Lung Cancer
MAIA Biotechnology Announces Positive Efficacy Updates for Phase 2 THIO-101 Trial in Advanced Non-Small Cell Lung Cancer ...
MAIA Biotechnology reports promising THIO trial results for NSCLC
CHICAGO - MAIA Biotechnology, Inc. (NYSE American: MAIA), a clinical-stage biopharmaceutical company with a market capitalization of $49.4 million, has announced updated data from its Phase 2 clinical ...
BioWorld1d
Updated Maia phase II data nudges its stock higher
New and positive data for Maia Biotechnology Inc.’s lead candidate for a particularly deadly and advanced lung cancer propelled the stock modestly higher on Feb. 4. The pivotal phase II THIO-101 study ...
Business Insider29d
MAIA Biotechnology enters clinical supply agreement with BeiGene for THIO
MAIA Biotechnology (MAIA) announced that it has entered into a clinical supply agreement with BeiGene (BGNE) to assess the efficacy of THIO, its small molecule telomere-targeting anticancer agent ...
Benzinga.com4mon
MAIA Biotechnology (AMEX:MAIA) Stock Quotes, Forecast and News Summary
MAIA Biotechnology's Phase 2 Study Of THIO In Non-Small Cell Lung Cancer Shows Positive Interim Survival Benefits MAIA Biotechnology's Lung Cancer Drug Shows Promising Long-Term Benefits In ...
Investing1d
MAIA Biotechnology rapporteert veelbelovende THIO-onderzoeksresultaten voor NSCLC
CHICAGO - MAIA Biotechnology, Inc. (NYSE American: MAIA), een biofarmaceutisch bedrijf in de klinische fase met een marktkapitalisatie van $49,4 miljoen, heeft bijgewerkte gegevens vrijgegeven van zij ...